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Summary.-Fifty-six patients with disseminated malignant melanoma were
randomly allocated to two treatment groups. The first group C received combina-
tion chemotherapy consisting of DTIC and ICRF 159. The second group (C + I)
received the same chemotherapy but were also immunized with 2 x 107 irradiated
allogeneic melanoma cells mixed with 50 ,ug of percutaneous BCG. The survival
rates in both treatment groups C and (C + I) were not significantly different, and
only minor enhancement of the chemotherapy was found in the (C + 1) group. A
similar pattern of tissue response was observed in both groups: lymph node, skin
and, to some extent liver metastases, respond better than other sites.
THE CURRENT treatments for dissemi-
nated malignant melanoma are unsatis-
factory. Analysis of the patients
followed up at the Westminster Hospital
in the pretrial period showed that the
2- and 5-year survivals for Stage IIb
were 51°/ and 200% respectively. The
one-year survival for Stage III was only
1000. These disappointing results are
similar to the experience ofothers (Boden-
ham, 1968; Johnson and Jacobs, 1971;
Luce, 1972). The most widely studied
drug in disseminated malignantmelanoma
is DTIC, which has induced an objective
regression rate in around 20% of cases in
a number of series (summarized in Comis
and Carter, 1974). These regressions are
commonly short-lived and numerous
attempts have been made to improve the
success rate by combining DTIC with
other agents. So far no marked en-
hancement of the DTIC effect has been
reported (Comis and Carter, 1974). How-
ever, animal experiments have shown
that ICRF 159 can enhance the cytotoxic
effect of DTIC (Wasserman et al., 1973).
ICRF 159 has not been reported in
combination with DTIC in malignant
melanoma. This study was designed both
to assess the efficiency of DTIC and
ICRF 159 as a combination in treating
melanoma and to see whether specific
active immunotherapy was a useful adju-
vant to the chemotherapy. Immuniza-
tion of melanoma patients with their own
irradiated tumour cells has been shown
to stimulate both cytotoxic antibody
(Ikonopisov et al., 1970) and cytotoxic
lymphocytes (Currie, Lejeune and
Fairley, 1971). More recent studies have
reported that both the combination of
chemotherapy with non-specific immuno-
therapy (Gutterman et al., 1973) and
specific active immunotherapy with
allogeneic melanoma cells (Currie and
McElwain, 1975) can improve the response
rates in malignant melanoma. In this
study the specific active immunotherapy
was based on the work of Currie and
McElwain (1975).
MATERIALS AND METHODS
Patients.-The study commenced in
January 1974. The staging of malignant
melanoma used is the Westminster Hospital
Classification (Butterworth et al., 1974).
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Stage I is primary melanoma; Stage Ila,
satellite skin nodules in the region of the
primary site; Stage IIb, involvement of
regional lymph nodes; Stage III, dissemina-
tion beyond the regional lymph nodes. Only
patients with Stage IIb and Stage III,
without evidence ofneurological involvement,
were admitted to the trial, and were randomly
allocated to either chemotherapy alone
(Group C) or chemotherapy plus immuno-
therapy (Group (C + I)). No patient had
received prior chemotherapy with the trial
drugs. Baseline investigations included full
blood count with bone marrow examination
as indicated, liver function tests, urea and
electrolytes, liver and bone scans and chest
x-ray. In view of the relative rarity of
malignant melanoma and the consistently
poor results reported in Stage IIb and
Stage III a group of untreated controls was
not included. Informed consent was ob-
tained from all patients before they entered
the trial.
Chemotherapy.-5 - (3,3 - Dimethyl - 1 -
triazeno) - imidazole - 4 - carboxamide
(DTIC), NSC-45388, was given i.v. at a dose
of 100 mg/M2 for 5 consecutive days. On
the same 5 days 1,2-di(3,5-dioxopiperazin-1-
yl) propane (ICRF 159), NSC-129943, was
given orally in a dose of 125 mg twice daily.
These courses were repeated at 5-week
intervals from Day 1. Anti-emetic drugs,
usually metoclopramide, were given to
reduce nausea and vomiting which was the
main side effect on the first two days of each
course. This drug combination induced
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little myelosuppression but dosage modifica-
tion was made if:
Dose
WBC less than 3,500/mm3 Half
WBC less than 2,500/mm3 Nil
Platelet count less than 100,000/mm3 Half
Platelet count less than 75,000/mm3 Nil
The only other common side effect was a
variable degree of lassitude that some
patients experienced following a course of
chemotherapy.
Immunotherapy.-Melanoma cells were
obtained from operative specimens. Cell
suspensions were made by teasing small
lumps of melanoma tissue in TC 199. The
cells were sedimented free of debris, washed
5 times and frozen in TC 199 containing
100% autologous serum and 100% dimethyl-
sulphoxide and stored in liquid N2 until
use. Following thawing and washing the
cells were counted and suspended in anti-
biotic-free TC 199 and irradiated with
12,000 rad in a 60Co source. Percutaneous
BCG (Glaxo) was reconstituted with saline
and diluted so that 50 jug was mixed with
the 2 x 107 melanoma cells. The mixture
of irradiated melanoma cells and BCG was
injected intradermally giving 0-1 ml to 8
sites 2-5 cm apart. Each limb was used in
rotation, excluding limbs where a block
dissection had been performed. The im-
munotherapy was given 11 days after the
end of the chemotherapy course. The
combined chemotherapy-immunotherapy
protocol is shown in Fig. 1. The timing of
immunotherapy has been shown to be
CELLS
ALONE
I,
0 1 2 3 4 5 6 7 8 9 10 11
LIII Lii
12 13 14 15 weeks
DTIC
D X ICRF 159
FIG. 1. Combinedl immuniotherapy chemotherapy protocol.
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important, to allow for recovery from the
immunosuppressive effects of chemotherapy
(Currie and Bagshawe, 1970). The interval
used here is based on the in vitro recovery of
cytotoxicity against melanoma cells following
DTIC and vincristine (Currie, G. A., personal
communication). Several patients were
studied for responses in the one-way mixed
lymphocyte reaction, and transformation of
their lymphocytes with PPD, and no evidence
of immunosuppression was found 11 days
after the chemotherapy.
Injections of melanoma cells mixed with
BCG induced variable and sometimes severe
local tissue necrosis and ulceration. As
these reactions increased with each course
the protocol was modified so that BCG was
given only with the first two courses of
immunotherapy. In subsequent courses
melanoma cells alone were given in the
same dose to 8 intradermal sites. The
melanoma cells alone did not induce any
severe local reactions.
Asses8ment ofresponse.-All patients were
fully assessed at the time of entry to the
trial and were reassessed immediately prior
to the next course of treatment.
Responses to treatment were defined as:
Complete response (CR) =
Disappearance of all clinically detectable
disease for a minimum of 10 weeks.
Partial response (PR) =
Unequivocal clinical response for a
minimum of 10 weeks confirmed by two
observers, but not excluding
progressive disease at other sites.
No response (NR) =
Stable or progressive disease.
Both treatment groups C and (C + I) were
continued in the trial until there was either
clearly progressive disease or they had
completed 12 months of treatment i.e.
10 x 5-week cycles.
RESULTS
Survival
Fifty-six patients were entered into
the trial between January 1974 and
March 1975, and follow-up information
was obtained in December 1975 when all
patients had been observed for at least
8 months. Fig. 2 is a dot diagram
representing the patient condition at last
follow-up of all patients in the trial.
Fig. 3 shows that the percentage
survival rates up to 16 months after
entry into the trial, are the same for both
treatment groups C and (C + I).
Fig. 4 shows the percentage sur-
vival rates of the 56 patients when
Survival Time (months)
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|Notation: @ Dead, * Alive, melanoma present, 0 Alive, no sign of recurrence
FIG. 2. Dot diagram for the 56 patients in the trial, followed up from January 1974 to December 1975.
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Notation: X Treatment Group :i
0 Treatment Group C+ I
29 Cases
27 Cases
0 2 4 6 8 10 12 14 16
Survival Time (months)
FIG. 3.-Survival of the two groups C and (C + I).
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39 | Stage III| Cases
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FIG. 4.-Survival by stage. (The vertical bars represent + one standard error.)
grouped according to stage, without sub-
division into treatment groups C and
(C + I). Even with the small number of
cases (17 Stage Ilb and 39 Stage III)
there is a significant difference between
survival rates at the 0.05 level of prob-
ability. All survival rates have been
calculated by an actuarial method, Green-
wood (1926) and Mould (1976).
Response
Only those who received 2 or more
courses oftreatment are included. Seven-
teen patients had to be excluded for the
following reasons: refused all treatment,
1; lost to follow-up, 1; irregular treatment,
1; received less than 2 courses, 14. The
number excluded from treatment group
C was 10 (1 Stage JIb and 9 Stage III).
There were 7 excluded from treatment
group (C + I) (2 Stage IIb and 5 Stage
III). Of the remaining 39 patients, 3
(2 group C and 1 group (C + I)) were
clinically disease-free, i.e. Stage Ilb post-
operatively and so could not be assessed
as responses. The results intheremaining
36 patients are shown in the Table. In
group C, 4/17 (23%) showed someresponse
(PR + CR). In group(C + I)9/19(47%)
responded. This gave an overall res-
ponse rate of 13/36 (36%). This com-
pares favourably with most of the
other reported trials using 2-drug
regimes in malignant melanoma (Comis
and Carter, 1974) although it must be
emphasized that the partial response
rate includes patients with progressive
disease elsewhere. Analysis of the sites
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TABLE. Responses in Patients Receiving 2 or more Courses of
Treatment
Sites
Treatment
group
No. Pts.
CR
PR
NR
C
3
1
Skin Nodes
(C -I) C (C + I)
1 2 3
1 1
- 1 2
2 1
Nodes
+
Skin Visceral
C (C + I) C (C + I)
5 2 3 1
1 -- 1
1
4 1 3
Visceral +
skin +
nodes
C (C + I)
4 12
__ 4*
4 8
* Includes 2 partial responses in non-visceral deposits.
which tend to respond to chemotherapy
are also shown in the Table. Skin and
lymph node involvement (in the absence
of visceral deposits) respond relatively
well: 8/16 (50%o) improved and in 4 of
these the responses were complete. How-
ever, the duration of these responses has
been relatively short. Those patients
with visceral involvement showed a re-
sponse rate of only 5/20 (25%). Of these
5, there was 1 CR and 1 PR in hepatic
deposits and 1 PR in pulmonary deposits;
the other 2 showed PR in their non-
visceral deposits.
DISCUSSION
A comparison of survival for the two
treatment groups, C aind (C + I), showed
no significant difference. A significant
difference in survival (P 0.05) was
however detected if the patients were
grouped by Stage, IIb or III, instead of
treatment group. The one-year survival
for Stage IIb was some 7500 and for Stage
III some 20%.
A trend was observed for both treat-
ment groups in that lymph node and skin
deposits were more responsive to treat-
ment than visceral deposits. The
numbers are, however, too small to make
significant statements, but the results are
consistent with those of other authors
(Wagner, Ramirez and Weiss, 1971;
Luce, 1972; Einhorn et al., 1974). Im-
munotherapy appears to increase the
response rate at certain sites and it
should be noted that the (C + I) group
contained more patients (13/19) with
visceral involvement than group C (7/17).
It is possible that, if immunotherapy was
only exerting a minor effect, this might
only be detected in patients with disease
at more responsive sites. The numbers
of patients with disease limited to skini
and lymph node are small but in group
(C + I) 4/6 (66%o) responded when com-
pared with 4/10 (400%) in group C.
The results show that the responses in
the combined groups C and (C + I) of
36% is lower thain the 57% response rate
reported by Currie and McElwain (1975).
Their group of patients were treated with
DTIC (at the same dosage as used here)
plus vincristine and all their patients
received immunotherapy with melanoma
cells plus BCCG. They had no control
group of chemotherapy alone. However,
when their series is analysed by the
tissue sites which responded to the
therapy, 12/17 of the responses were in
skin and lymph node and only 5 in
visceral deposits. The similarity in the
pattern of responses in both groups in
this study and in Currie and McElwain's
(1975) series implies that the major
active agent in both protocols is the
chemotherapy (probably mainly DTIC).
As suggested above, the immunotherapy
used may play a minor role by increasing
the response of certain sites to chemo-
therapy, but it has not altered the
survival rate. There is evidence that
non-specific immunotherapy with BCG
can enhance the effect of DTIC (Gutter-
man et al., 1973 and 1974). Further con-
trolled trials are necessary to demonstrate
whether or not this type of immuno-
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therapy has any role in treating dissemi-
nated malignant melanoma.
The addition of ICRF 159 to DTIC
did not increase the toxicity at the
dosage used. However, at this relatively
low dose of DTIC the response rate has
been comparable to that in a number of
other series using higher doses of DTIC
(Comis and Carter, 1974). The major
toxicity encountered was nausea and
vomiting on the first 2 days of each
course. This was attributed to the DTIC.
A further study of this drug combination
using dose escalation will be required to
show whether or not ICRF 159 can
enhance the response rate to DTIC.
We should like to thank Imperial
Chemical Industries for the supply of
ICRF 159, the National Cancer Institute,
Bethesda, for the supply of DTIC, Pro-
fessor K. Hellmann of the Imperial
Cancer Research Fund for his advice and
Miss C. Portman for her assistance in
organizing the trial and for typing this
manuscript.
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